Silexion Therapeutics reports promising data on siRNA candidate for KRAS-driven cancers, showing tumor growth reduction

From GlobeNewswire: 2025-01-28 08:29:00

Silexion Therapeutics Corp. announced promising preclinical data for SIL-204, a siRNA therapeutic candidate targeting KRAS-driven cancers. The data showed significant tumor growth reduction in orthotopic pancreatic cancer models, validating systemic administration as an effective delivery approach. SIL-204 targets key oncogenic KRAS mutations and has shown promising results in reducing tumor growth and increasing tumor necrosis. The company is optimistic about expanding its next-generation treatment strategy for KRAS-driven cancers based on these results. Further studies will evaluate the impact on metastatic progression.

Silexion Therapeutics is a biotechnology company developing RNA interference therapies for solid tumors driven by KRAS mutations. The company’s first-generation product, LODER™, has shown promise in non-resectable pancreatic cancer. SIL-204 is the next-generation siRNA candidate targeting a broader range of KRAS mutations. Silexion remains committed to advancing therapeutic innovation in oncology to improve outcomes for patients with difficult-to-treat cancers. The company plans to announce details of its expanded development plan shortly.



Read more at GlobeNewswire: Silexion Therapeutics Reports Strong Tumor Growth Reduction